HS
DAWN

Horan Securities’s Day One Biopharmaceuticals DAWN Stock Holding History

Horan Securities’s Portfolio DAWN Stock Details DAWN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-17
Closed -$366 – 766
2022
Q4 		$366 Buy
+17
New +$349 ﹤0.01% 733

Other funds holding DAWN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CPX
Canaan Partners XI Menlo Park, California $76.1M AUM 638.59% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Horan Securities's DAWN Position: Q1 2023 in Review

Horan Securities sold out of Day One Biopharmaceuticals (DAWN) in Q1 2023, closing a stake of 17 shares — an estimated $366 sold.

Horan Securities first reported a position in DAWN in Q4 2022 and held it in 1 quarter. The position peaked at $366 in Q4 2022. 126 funds tracked by Wall St. Rank hold DAWN as of Q1 2023.

  • Horan Securities reported no remaining Day One Biopharmaceuticals position as of Q1 2023 after selling out during the quarter.
  • Horan Securities sold 17 Day One Biopharmaceuticals shares in Q1 2023, an estimated $366.
  • Horan Securities first reported a position in Day One Biopharmaceuticals in Q4 2022 and held it in 1 quarter.
  • Horan Securities's Day One Biopharmaceuticals position peaked at $366 in Q4 2022.
  • 126 funds tracked by Wall St. Rank held Day One Biopharmaceuticals as of Q1 2023.

Based on Horan Securities's 13F filing for Q1 2023, filed 18 Apr 2023.